Fennec Pharmaceuticals Partners with Tampa General Hospital to Study PEDMARK in Adult Cancer Patients
Event summary
- Fennec Pharmaceuticals collaborates with Tampa General Hospital to study PEDMARK in reducing ototoxicity in adult cancer patients receiving cisplatin-based treatment.
- The study will evaluate real-world clinical data and audiology monitoring to inform future research and quality efforts.
- PEDMARK is currently approved for pediatric patients and has a 2A recommendation for AYA patients from the National Comprehensive Cancer Network.
- Fennec has exclusive licensing agreements with Norgine Pharmaceuticals for commercialization in Europe, U.K., Australia, and New Zealand.
The big picture
Fennec Pharmaceuticals' collaboration with Tampa General Hospital marks a strategic shift towards expanding the clinical utility of PEDMARK beyond its current pediatric approval. This move aligns with broader industry trends of leveraging real-world evidence to support drug efficacy in diverse patient populations. The study could significantly impact the company's commercial strategy, particularly in markets where Norgine Pharmaceuticals holds exclusive rights. Success in this initiative may position Fennec as a leader in otoprotective therapies for cancer patients.
What we're watching
- Clinical Validation
- Whether the study will provide robust evidence supporting PEDMARK's efficacy in adult cancer patients, potentially expanding its approved indications.
- Market Expansion
- The pace at which Fennec can leverage real-world data to drive adoption of PEDMARK in broader patient populations beyond pediatric use.
- Commercial Strategy
- How Fennec and Norgine will capitalize on the study results to strengthen PEDMARK's market position in regions covered by their licensing agreement.
Related topics